Preterm Birth Clinical Trial
Official title:
First-trimester Prediction of Preeclampsia and Other Placenta-mediated Pregnancy Complications
Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death. Several measures are used or under investigation (low-dose aspirin, low-molecular weight heparin, calcium, folic acid, among others) for the prevention of preeclampsia. Unfortunately, most high-risk women who could benefit from those preventive measures are not identified until late in pregnancy. Recent evidences suggest that the investigators could identify women at risk of developing preeclampsia using a combination of serum and ultrasound biomarkers in the first-trimester of pregnancy. This screening test needs external validation. A first-trimester screening strategy will strengthen clinical research on preeclampsia and will contribute to the development of strategy combining the prediction and prevention of the disease and its related complications.
Background: Preeclampsia (PE) is a placenta-mediated pregnancy complication related to
adverse maternal and neonatal outcomes, including intra-uterine growth restriction (IUGR) and
perinatal death. A growing body of evidence suggests that the preterm and severe forms of PE
are associated with deep placentation disorders that occur early in gestation. Over the last
decade, maternal characteristic and first-trimester biomarkers, including some that are
already used for aneuploidy screening (PAPP-A) have been strongly related to the preterm and
early forms of PE, suggesting that early prediction is possible. Preventive measures are
actually recommended (low-dose aspirin; calcium) or under investigation (folic acid;
low-molecular weight heparin; anti-oxidant) in high-risk women. However, only women with
chronic disease or prior adverse pregnancy outcomes are eligible for these measures while
most cases of PE occur in nulliparous women. Moreover, there are actually no clear guidelines
for clinicians in Canada whose pregnant patients have one or several risk factors for
preeclampsia (obesity, chronic hypertension, low PAPP-A, etc.). On the other hand, it has
been suggested that prediction of PE, and particularly the most severe cases, is possible
with high sensitivity and specificity by using a combination of anamnestic, biophysical,
biochemical and ultrasonographic biomarkers using the web-based Fetal-Medicine Foundation
(FMF) screening test. This suggests that a strategy of prediction and prevention of PE and
other placenta-mediated complications is becoming possible for nulliparous women as well.
However, certain major concerns must be addressed: 1) The FMF screening test has not been
validated prospectively; 2) a controversy exists about the need and feasibility of Doppler
ultrasound in the general population.
Objectives:
1. To validate the 11-13 week FMF screening test for early-onset PE and a composite of
placenta-mediated outcomes (preterm PE, IUGR <3rd percentile, stillbirth); and
2. To compare the screening test with and without uterine artery (UtA) Doppler;
3. To explore the efficiency of new potential biomarkers (ADAM-12; Placental protein (PP)
-13; placental and subplacental volume; placental vascularization) for prediction of PE
in our population.
Methods: A multicenter prospective observational study of nulliparous women recruited between
11 3/7 - 13 6/7 weeks (maternal characteristics; BMI; Mean arterial pressure (MAP); PAPP-A;
placental growth factor (PIGF); UtA Doppler…) and followed until delivery. Delivery and
neonatal data will be collected through chart reviews. Detection rates for early-onset PE
(primary outcome) and other adverse pregnancy outcomes will be measured using the 11-13 weeks
FMF screening test with and without UtA Doppler results. A case-cohort study will be
performed using stored serum samples and three-dimensional ultrasound volume acquired at the
11-13 weeks visit.
Feasibility and power calculation: We estimate a minimum incidence of early-onset PE of 0.7%.
A minimum of 7,600 women will be necessary to demonstrate that the FMF screening test is at
least 80% sensitive and 90% specific where it is expected that it will be 95% sensitive and
92% specific. We will have the power to detect an absolute difference of 15% in the detection
rate between the different screening strategies (± Doppler). Recruitment will take 3.0 years.
The overall study will take 5.0 years.
Expectations: First, our research will potentially provide a validated, highly sensitive and
specific, and cheap tool to help clinicians' decision in the care of nulliparous women with
risk factors for PE. In case of negative results, the clinician will have good evidence to
reassure the patients facing abnormal maternal serum screening values. The validation of a
first-trimester screening strategy will strengthen clinical research on PE providing new
information on the natural evolution of the disease. Finally, this study will contribute to
develop the optimal design for randomized trials aiming at the prevention of early-onset PE
and other placenta-mediated complications of pregnancy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Completed |
NCT05502510 -
Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
|
||
Not yet recruiting |
NCT03418311 -
Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome
|
N/A | |
Not yet recruiting |
NCT03418012 -
Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB
|
N/A | |
Completed |
NCT02993744 -
Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone
|
N/A | |
Active, not recruiting |
NCT02673216 -
Infection and Adverse Pregnancy Outcome
|
||
Completed |
NCT01683565 -
Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood
|
Phase 4 | |
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Completed |
NCT01412931 -
Protein and Ultrasound Indicators of Preterm Birth
|
N/A | |
Completed |
NCT02606058 -
The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?
|
N/A | |
Terminated |
NCT03715530 -
Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women
|
N/A | |
Completed |
NCT00422526 -
Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04251260 -
Effectiveness of Positioning in Preterm Neonates
|
N/A | |
Completed |
NCT03668860 -
India Dexamethasone and Betamethasone
|
Phase 1 | |
Recruiting |
NCT03638037 -
Correlation Between Maternal Vitamin D Level And Preterm Birth
|
||
Completed |
NCT02225353 -
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
|
Phase 2 | |
Recruiting |
NCT03992534 -
The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth
|
Phase 1 | |
Completed |
NCT03144141 -
Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery
|
N/A | |
Completed |
NCT05210985 -
Examination of the Relationship Between Home Affordances With Development
|
||
Completed |
NCT04021654 -
What is the Future of Vulnerable New-borns
|